open access

Vol 50, No 3 (2016)
Original research articles
Submitted: 2015-06-04
Get Citation

Efficacy of the greater occipital nerve block in recurrent migraine type headaches

Korgun Okmen, Yasar Dagistan, Emine Dagistan, Necati Kaplan, Emre Cancan
DOI: 10.1016/j.pjnns.2016.01.015
·
Neurol Neurochir Pol 2016;50(3):151-154.

open access

Vol 50, No 3 (2016)
Original research articles
Submitted: 2015-06-04

Abstract

Aims

We aimed to evaluate six months of results following repeated GON blocks.

Methods

We evaluated the results from GON block performed on 60 patients. Briefly, we applied a standard 2mL of 0.5% Bupivacaine GON blockage once a week for 4 weeks. We recorded the Visual Analog Scale (VAS) scores, the number of migraine attacks and the Migraine Disability Assessment Questionnaire (MIDAS) scores. The study subjects were not allowed to use medication for prophylaxis, and Ibuprofen (400mg, 1200mg at maximum) was prescribed for any migraine attacks.

Results

The initial mean number of attacks per month before starting treatment was 8.33+2.31. After treatment, the initial MIDAS mean was found to be 2.82 per month; this declined to 1.47 in 3rd, and was 1.50 in the 6th month. The individual month values were found to be significant, and were listed respectively as, 1st month: 3.95+2.52, 2nd month: 3.23+1.82, 3rd month: 2.60+1.90, 4th month: 2.68+2.10, 5th month: 2.58+1.90 and 6th month: 2.58+1.90. The mean VAS scores were recorded as follows for each month: 6.28±1.24, 3.13±0.97, 2.55±1.19, 2.35±1.26, 2.38±1.20 and 2.48±1.30, respectively. This difference was noted to be statistically significant. No difference regarding the efficacy of the treatment was determined when the results were compared across age groups.

Conclusion

We assume that GON blockage with 2mL of 0.5% Bupivacaine can be a supportive treatment in migraine treatment, with no serious adverse effects reported.

Abstract

Aims

We aimed to evaluate six months of results following repeated GON blocks.

Methods

We evaluated the results from GON block performed on 60 patients. Briefly, we applied a standard 2mL of 0.5% Bupivacaine GON blockage once a week for 4 weeks. We recorded the Visual Analog Scale (VAS) scores, the number of migraine attacks and the Migraine Disability Assessment Questionnaire (MIDAS) scores. The study subjects were not allowed to use medication for prophylaxis, and Ibuprofen (400mg, 1200mg at maximum) was prescribed for any migraine attacks.

Results

The initial mean number of attacks per month before starting treatment was 8.33+2.31. After treatment, the initial MIDAS mean was found to be 2.82 per month; this declined to 1.47 in 3rd, and was 1.50 in the 6th month. The individual month values were found to be significant, and were listed respectively as, 1st month: 3.95+2.52, 2nd month: 3.23+1.82, 3rd month: 2.60+1.90, 4th month: 2.68+2.10, 5th month: 2.58+1.90 and 6th month: 2.58+1.90. The mean VAS scores were recorded as follows for each month: 6.28±1.24, 3.13±0.97, 2.55±1.19, 2.35±1.26, 2.38±1.20 and 2.48±1.30, respectively. This difference was noted to be statistically significant. No difference regarding the efficacy of the treatment was determined when the results were compared across age groups.

Conclusion

We assume that GON blockage with 2mL of 0.5% Bupivacaine can be a supportive treatment in migraine treatment, with no serious adverse effects reported.

Get Citation

Keywords

Bupivacaine, Migraine, Migraine Disability Assessment Questionnaire, Occipital nerve block, Visual Analog Scale

About this article
Title

Efficacy of the greater occipital nerve block in recurrent migraine type headaches

Journal

Neurologia i Neurochirurgia Polska

Issue

Vol 50, No 3 (2016)

Pages

151-154

DOI

10.1016/j.pjnns.2016.01.015

Bibliographic record

Neurol Neurochir Pol 2016;50(3):151-154.

Keywords

Bupivacaine
Migraine
Migraine Disability Assessment Questionnaire
Occipital nerve block
Visual Analog Scale

Authors

Korgun Okmen
Yasar Dagistan
Emine Dagistan
Necati Kaplan
Emre Cancan

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl